M Dowsett

Summary

Affiliation: Institute of Cancer Research
Country: UK

Publications

  1. pmc Combination therapy with aromatase inhibitors: the next era of breast cancer treatment?
    A Leary
    Academic Department of Biochemistry, Royal Marsden Hospital Institute of Cancer Research, London, UK
    Br J Cancer 95:661-6. 2006
  2. pmc Microarray-based comparative genomic hybridisation of breast cancer patients receiving neoadjuvant chemotherapy
    J Y Pierga
    Breakthrough Breast Cancer Research Center, The Institute of Cancer Research, London, SW3 6JB, UK
    Br J Cancer 96:341-51. 2007
  3. pmc Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer
    S Barton
    Department of Medicine, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
    Br J Cancer 106:1760-5. 2012
  4. ncbi request reprint Sex hormones and breast cancer risk and prognosis
    Elizabeth Folkerd
    The Academic Department of Biochemistry, The Royal Marsden NHS Foundation Trust, Wallace Wing, Fulham Road, London SW3 6JJ, UK Electronic address
    Breast 22:S38-43. 2013
  5. pmc Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study
    Katja Lundgren
    Center for Molecular Pathology, Department of Laboratory Medicine, Lund University, Malmo University Hospital, SE 205 02 Malmo, Sweden
    Breast Cancer Res 14:R57. 2012
  6. pmc Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer
    Marion T Weigel
    Breakthrough Breast Cancer Centre, Institute of Cancer Research, 237 Fulham Road, London SW3 6JJ, UK
    Breast Cancer Res 14:R78. 2012
  7. pmc ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
    Isabel Pinhel
    Academic Department of Biochemistry, The Royal Marsden Hospital, Fulham Road, London, SW3 6JJ, UK
    Breast Cancer Res 14:R46. 2012
  8. pmc Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer
    Isabel F Pinhel
    Department of Academic Biochemistry, Institute of Cancer Research, London, UK
    Breast Cancer Res 12:R76. 2010
  9. doi request reprint Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy
    Mitch Dowsett
    Academic Department of Biochemistry, Royal Marsden Hospital, and Breakthrough Breast Cancer Centre, Institute of Cancer Research, London, SW3 6JJ, United Kingdom
    J Clin Oncol 31:2783-90. 2013
  10. pmc Tamoxifen may prevent both ER+ and ER- breast cancers and select for ER- carcinogenesis: an alternative hypothesis
    Laura J Esserman
    Deptartment of Surgery, University of California San Francisco Medical Center, San Francisco, CA, USA
    Breast Cancer Res 7:R1153-8. 2005

Collaborators

Detail Information

Publications178 found, 100 shown here

  1. pmc Combination therapy with aromatase inhibitors: the next era of breast cancer treatment?
    A Leary
    Academic Department of Biochemistry, Royal Marsden Hospital Institute of Cancer Research, London, UK
    Br J Cancer 95:661-6. 2006
    ..In time, breast cancer treatment will become truly individualised because physicians will be able to match patients with a variety of disease phenotypes to optimal combination therapies...
  2. pmc Microarray-based comparative genomic hybridisation of breast cancer patients receiving neoadjuvant chemotherapy
    J Y Pierga
    Breakthrough Breast Cancer Research Center, The Institute of Cancer Research, London, SW3 6JB, UK
    Br J Cancer 96:341-51. 2007
    ..2-11p15.5. The modest chemotherapy-driven genomic changes, despite profound loss of cell numbers, suggest that there is little therapeutic selection of resistant non-modal cell lineages...
  3. pmc Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer
    S Barton
    Department of Medicine, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
    Br J Cancer 106:1760-5. 2012
    ..We assessed its utility in personalising breast cancer treatment in a clinical practice setting, through comparison with Adjuvant! Online (AoL) and the Nottingham Prognostic Index (NPI)...
  4. ncbi request reprint Sex hormones and breast cancer risk and prognosis
    Elizabeth Folkerd
    The Academic Department of Biochemistry, The Royal Marsden NHS Foundation Trust, Wallace Wing, Fulham Road, London SW3 6JJ, UK Electronic address
    Breast 22:S38-43. 2013
    ....
  5. pmc Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study
    Katja Lundgren
    Center for Molecular Pathology, Department of Laboratory Medicine, Lund University, Malmo University Hospital, SE 205 02 Malmo, Sweden
    Breast Cancer Res 14:R57. 2012
    ..CCND1 amplification and protein overexpression have also been associated with resistance to treatment with tamoxifen or even to a potentially detrimental effect of tamoxifen...
  6. pmc Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer
    Marion T Weigel
    Breakthrough Breast Cancer Centre, Institute of Cancer Research, 237 Fulham Road, London SW3 6JJ, UK
    Breast Cancer Res 14:R78. 2012
    ..Estrogen (E) mediates its effects by binding to the ER. Therapies targeting the estrogenic stimulation of tumor growth reduce mortality from ER+ breast cancer. However, resistance remains a major clinical problem...
  7. pmc ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
    Isabel Pinhel
    Academic Department of Biochemistry, The Royal Marsden Hospital, Fulham Road, London, SW3 6JJ, UK
    Breast Cancer Res 14:R46. 2012
    ..However, we investigated the quantitative relation between ER and HER2 expression at both RNA and protein levels in HER2+ve and HER2-ve breast carcinomas...
  8. pmc Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer
    Isabel F Pinhel
    Department of Academic Biochemistry, Institute of Cancer Research, London, UK
    Breast Cancer Res 12:R76. 2010
    ..The aim of this study was to characterize the differences in immunoreactivity of common biomarkers that may occur (a) due to tissue handling at surgery and (b) between core-cuts and resected tumours...
  9. doi request reprint Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy
    Mitch Dowsett
    Academic Department of Biochemistry, Royal Marsden Hospital, and Breakthrough Breast Cancer Centre, Institute of Cancer Research, London, SW3 6JJ, United Kingdom
    J Clin Oncol 31:2783-90. 2013
    ..It is frequently estimated using the Oncotype DX recurrence score (RS). The PAM50 risk of recurrence (ROR) score provides an alternative approach, which also identifies intrinsic subtypes...
  10. pmc Tamoxifen may prevent both ER+ and ER- breast cancers and select for ER- carcinogenesis: an alternative hypothesis
    Laura J Esserman
    Deptartment of Surgery, University of California San Francisco Medical Center, San Francisco, CA, USA
    Breast Cancer Res 7:R1153-8. 2005
    ....
  11. pmc Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer
    Russell Burcombe
    Kent Oncology Centre, Maidstone Hospital, Hermitage Lane, Maidstone, Kent ME16 9QQ, UK
    Breast Cancer Res 8:R31. 2006
    ..This study evaluated changes in Ki-67 labeling index and apoptotic index (AI) before, during, and after neoadjuvant anthracycline chemotherapy...
  12. pmc Sex steroids, growth factors and mammographic density: a cross-sectional study of UK postmenopausal Caucasian and Afro-Caribbean women
    Valerie A McCormack
    Cancer Research UK Epidemiology and Genetics Group, Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK
    Breast Cancer Res 11:R38. 2009
    ..If such a hormonal basis of mammographic density exists, hormones may underlie ethnic differences in both mammographic density and breast cancer incidence rates...
  13. pmc Molecular response to aromatase inhibitor treatment in primary breast cancer
    Alan Mackay
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, London, SW3 6JB, UK
    Breast Cancer Res 9:R37. 2007
    ..Little is known of the molecular effects of these agents on human breast carcinomas in vivo...
  14. pmc The effect of the stromal component of breast tumours on prediction of clinical outcome using gene expression microarray analysis
    Susan J Cleator
    Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, SW3 6JB, London, UK
    Breast Cancer Res 8:R32. 2006
    ..The aim of this study was to examine the effect of the cellular composition of biopsies on the error rates of multigene predictors of response of breast tumours to neoadjuvant adriamycin and cyclophosphamide (AC) chemotherapy...
  15. pmc Revisiting the technical validation of tumour biomarker assays: how to open a Pandora's box
    Caterina Marchio
    Department of Biomedical Sciences and Human Oncology, University of Turin, Via Santena 7, 10126 Turin, Italy
    BMC Med 9:41. 2011
    ..Here we discuss the challenges for the technical validation of immunohistochemical and gene expression assays to detect tumour biomarkers and provide suggestions of pragmatic solutions to address these challenges...
  16. ncbi request reprint Standardization of HER2 testing: results of an international proficiency-testing ring study
    Mitch Dowsett
    Academic Depertment of Biochemistry, Royal Marsden Hospital, London, UK
    Mod Pathol 20:584-91. 2007
    ..7-2.3 by at least one center. Equivocal immunohistochemistry and borderline FISH cases are difficult to interpret, even for highly experienced and validated laboratories, highlighting the need for quality-control procedures...
  17. ncbi request reprint The biology of steroid hormones and endocrine treatment of breast cancer
    Mitch Dowsett
    Department of Biochemistry, Royal Marsden Hospital, London SW3 6JJ, UK
    Breast 14:452-7. 2005
    ..In contrast, tamoxifen can lead to markedly enhanced levels. In postmenopausal women aromatase inhibitors can achieve an almost complete inhibition of the aromatase enzyme...
  18. ncbi request reprint Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen
    Mitch Dowsett
    Academic Department of Biochemistry, Royal Marsden Hospital, London, United Kingdom
    J Clin Oncol 28:509-18. 2010
    ..To conduct meta-analyses of randomized trials of aromatase inhibitors (AIs) compared with tamoxifen either as initial monotherapy (cohort 1) or after 2 to 3 years of tamoxifen (cohort 2)...
  19. ncbi request reprint Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience
    M Dowsett
    Academic Department of Biochemistry, Royal Marsden Hospital, London SW3 6JJ, UK
    Endocr Relat Cancer 12:S113-7. 2005
    ..There is an unfortunate paucity of clinical and biological data on acquired resistance to aromatase inhibitors...
  20. pmc International Web-based consultation on priorities for translational breast cancer research
    Mitch Dowsett
    Academic Department of Biochemistry, Royal Marsden Hospital, London SW3 6JJ, UK
    Breast Cancer Res 9:R81. 2007
    ..We therefore conducted an international Web-based consultation of breast cancer professionals to identify the topics most widely considered to be of highest priority...
  21. ncbi request reprint Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial
    Mitch Dowsett
    Academic Department of Biochemistry, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, United Kingdom
    J Clin Oncol 26:1059-65. 2008
    ....
  22. pmc Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial
    Mitch Dowsett
    Department of Academic Biochemistry, Royal Marsden Hospital, London, UK
    J Clin Oncol 27:2962-9. 2009
    ....
  23. ncbi request reprint Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study
    Mitch Dowsett
    Royal Marsden Hospital, Wolfson Institute for Preventive Medicine, Queen Mary University of London London
    J Clin Oncol 28:1829-34. 2010
    ....
  24. ncbi request reprint Biomarker investigations from the ATAC trial: the role of TA01
    Mitch Dowsett
    Academic Biochemistry, The Royal Marsden Hospital, Fulham Road, SW3 6JJ, London, UK
    Breast Cancer Res Treat 87:S11-8. 2004
    ..Ultimately, the TA01 program has the potential to favorably impact treatment choices for breast cancer...
  25. ncbi request reprint Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival
    Mitch Dowsett
    Academic Department of Biochemistry, Royal Marsden Hospital, London
    Clin Cancer Res 11:951s-8s. 2005
    ....
  26. pmc Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group
    Mitch Dowsett
    Department of Biochemistry, Royal Marsden Hospital and Breakthrough Breast Cancer Centre, Fulham Road, London, UK
    J Natl Cancer Inst 103:1656-64. 2011
    ..These recommendations are geared toward achieving a harmonized methodology, create greater between-laboratory and between-study comparability, and allow earlier valid applications of this marker in clinical practice...
  27. ncbi request reprint Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists
    Mitch Dowsett
    Academic Department of Biochemistry and the Breast Unit, Royal Marsden Hospital, London SW3 6JJ, UK
    J Clin Oncol 23:2477-92. 2005
    ..To investigate the relationships between biomarker changes in breast cancer during neoadjuvant (preoperative) endocrine therapy...
  28. pmc Deficits in plasma oestradiol measurement in studies and management of breast cancer
    Mitch Dowsett
    Academic Department of Biochemistry, The Royal Marsden Hospital, London, UK
    Breast Cancer Res 7:1-4. 2005
    ..The importance of using appropriate methodology is discussed and illustrated with data demonstrating the disparity in the results obtained when low levels of oestradiol were quantified using direct and indirect methods...
  29. pmc HER2 testing in the UK: consensus from a national consultation
    Mitch Dowsett
    The Royal Marsden NHS Trust, Fulham Road, London SW3 6JJ, UK
    J Clin Pathol 60:685-9. 2007
    ..To gain an understanding of current attitudes among oncologists and pathologists to prospective HER2 testing in breast cancer and to gauge whether a national consensus exists regarding extent and quality of testing...
  30. ncbi request reprint Mechanisms of resistance to aromatase inhibitors
    Mitch Dowsett
    Academic Department of Biochemistry, Royal Marsden Hospital, London SW3 6JJ, UK
    J Steroid Biochem Mol Biol 95:167-72. 2005
    ..Collection of resistant biopsy tissues from patients is important to determine if this mechanism is clinically relevant...
  31. ncbi request reprint Designing the future shape of breast cancer diagnosis, prognosis and treatment
    Mitch Dowsett
    Academic Biochemistry, Royal Marsden Hospital, Fulham Road, SW3 6JJ, London, UK
    Breast Cancer Res Treat 87:S27-9. 2004
    ..The resulting incorporation of new biomarkers and revised trial designs should promote the future development of more precise and increasingly active interventions directed towards the treatment of breast cancer...
  32. doi request reprint Predictive algorithms for adjuvant therapy: TransATAC
    Mitch Dowsett
    Academic Department of Biochemistry, Royal Marsden Hospital, Fulham Road, London SW36JJ, UK
    Steroids 76:777-80. 2011
    ..Integration of each of these molecular profiles with classical clinicopathologic variables provided the most accurate prediction of outcome...
  33. doi request reprint Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer
    Mitch Dowsett
    Academic Department of Biochemistry, Royal Marsden Hospital, London SW3 6JJ, UK
    J Natl Cancer Inst Monogr 2011:120-3. 2011
    ..It provides a unique opportunity for detailed study of the determinants of response and resistance to estrogen deprivation as well as testing the role of presurgical therapy for improved biomarker-based estimates of prognosis...
  34. ncbi request reprint Translational research and the changing face of breast cancer
    Mitch Dowsett
    Academic Biochemistry, The Royal Marsden Hospital, SW3 6JJ, Fulham Road, London, UK
    Breast Cancer Res Treat 87:S1-2. 2004
    ..In this way, the treatments available should be efficiently and actively revised to incorporate new concepts of diagnosis, prognosis and treatment, to the benefit of women with breast cancer...
  35. ncbi request reprint Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study
    Mitch Dowsett
    Royal Marsden Hospital London, SW3 6JJ United Kingdom
    J Clin Oncol 23:7512-7. 2005
    ..We retrospectively tested the hypothesis that this benefit might differ according to PgR status...
  36. ncbi request reprint Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer
    Mitch Dowsett
    Academic Department of Biochemistry and Breast Unit, Royal Marsden Hospital, London SW3 6JJ, United Kingdom
    Clin Cancer Res 12:1024s-1030s. 2006
    ..We argue that these changes in proliferation and concurrent changes in apoptosis may be expected to be more predictive of adjuvant benefit from endocrine therapy than clinical response...
  37. ncbi request reprint Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer
    Mitch Dowsett
    Academic Department of Biochemistry, 4th Floor, Wallace Wing, The Royal Marsden Hospital, Fulham Road, London SW3 6 JJ, UK
    J Natl Cancer Inst 99:167-70. 2007
    ....
  38. ncbi request reprint Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer
    J Chang
    Departments of Medicine and Computing, The Royal Marsden Hospital, Sutton, Surrey, United Kingdom
    J Clin Oncol 17:3058-63. 1999
    ..To determine whether pretreatment clinical features and molecular markers, together with changes in these factors, can predict treatment response and survival in patients with primary operable breast cancer who receive neoadjuvant therapy...
  39. pmc EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy
    A H Evans
    Breakthrough Breast Cancer Centre, Institute of Cancer Research, London, UK
    Br J Cancer 102:1235-43. 2010
    ..We investigated whether AEE788 (a combined inhibitor of EGFR, HER2 and VEGFR) plus tamoxifen or letrozole enhanced the individual anti-tumour effects of these agents...
  40. ncbi request reprint Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis
    S R Johnston
    Department of Medicine, The Royal Marsden NHS Trust, London, England
    Cancer Res 59:3646-51. 1999
    ..Sustained induction of apoptosis may contribute to prolonged antagonism of E2-dependent growth, and it occurred to a greater extent following 3 months of idoxifene, compared to tamoxifen...
  41. ncbi request reprint HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer
    M Dowsett
    Breast Unit, Royal Marsden Hospital, London, United Kingdom
    Cancer Res 61:8452-8. 2001
    ..This together with high baseline proliferation is likely to translate to poor clinical response...
  42. pmc Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione ('pyridoglutethimide') in postmenopausal breast cancer patients
    M Dowsett
    Academic Department of Biochemistry, Royal Marsden Hospital, London, UK
    Br J Cancer 64:887-94. 1991
    ..d., two at 800 mg b.d., and one at 1200 mg b.d. The most frequent side-effects were nausea and lethargy. One patient showed an objective response to treatment...
  43. ncbi request reprint Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation
    Christina M W Chan
    Department of Academic Biochemistry, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
    J Steroid Biochem Mol Biol 81:333-41. 2002
    ..Thus, the resistance of these human breast cancer cells to oestrogen-deprivation appears to be due to acquired hypersensitivity which may be explained in part by increased levels of and phosphorylated ERalpha...
  44. ncbi request reprint Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma
    J Chang
    Department of Biochemistry, Medicine and Computing, The Royal Marden Hospital, Sutton, Surrey, United Kingdom
    Cancer 89:2145-52. 2000
    ..The objective of this clinical study was to examine in vivo changes in apoptotic index (AI), Bcl-2 expression, proliferation (Ki-67 and S-phase fraction [SPF]), and ploidy as potential indicators of chemoresponsiveness...
  45. ncbi request reprint Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response
    A Makris
    Royal Marsden Hospital, Sutton, Surrey, UK
    Breast Cancer Res Treat 48:11-20. 1998
    ..To determine the effects of tamoxifen on the levels of hormone receptors and proliferation markers in the early phase of treatment and the relationship of the changes with tumor response in patients with primary breast cancer...
  46. ncbi request reprint Antiproliferative effects of idoxifene in a placebo-controlled trial in primary human breast cancer
    M Dowsett
    Department of Academic Biochemistry, Royal Marsden Hospital, London, United Kingdom
    Clin Cancer Res 6:2260-7. 2000
    ..05 < P < 0.10). Idoxifene was well tolerated in all patients. Idoxifene has an antiproliferative effect in ER-positive but not ER-negative breast cancers, and no significant effect on apoptosis in the short-term...
  47. ncbi request reprint Role of biologic markers in patient selection and application to disease prevention
    Mitch Dowsett
    Joint Institute of Cancer Research Royal Marsden NHS Trust, Academic Department of Biochemistry, London, United Kingdom
    Am J Clin Oncol 26:S34-9. 2003
    ..Gene expression profiling (microarray analysis), i.e., genomic and proteomic studies, will probably advance the discovery of new biomarkers for breast cancer prevention and treatment...
  48. pmc Comparison of MIB-1 proliferation index with S-phase fraction in human breast carcinomas
    P A Ellis
    Academic Department of Biochemistry, Royal Marsden NHS Trust, Sutton, UK
    Br J Cancer 73:640-3. 1996
    ..This can be done using simple, widely available technology and provides the opportunity to perform large-scale retrospective analyses of archival materials...
  49. ncbi request reprint Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status
    M Dowsett
    Academic Department of Biochemistry, The Royal Marsden NHS Trust, London, UK
    Ann Oncol 17:818-26. 2006
    ..The measurement of tumour biomarkers should allow better selection of patients for such treatment or for therapies such as aromatase inhibitors...
  50. ncbi request reprint Aromatase inhibitors and male breast cancer
    E Arriola
    Department of Biochemistry, Royal Marsden Hospital, Fulham Road, London, UK
    Clin Transl Oncol 9:192-4. 2007
    ..Here we report a case of a male patient with metastatic breast cancer treated with letrozole who achieved clinical response associated with a decrease in blood oestradiol levels...
  51. ncbi request reprint Analysis and sorting of apoptotic cells from fine-needle aspirates of excised human primary breast carcinomas
    M Dowsett
    Academic Department of Biochemistry, Royal Marsden Hospital, London, United Kingdom
    Cytometry 32:291-300. 1998
    ..3-11.3% by flow cytometry) and between different phases of treatment, and should provide a useful tool for further research on this process in solid tumours...
  52. doi request reprint An in vitro model showing adaptation to long-term oestrogen deprivation highlights the clinical potential for targeting kinase pathways in combination with aromatase inhibition
    L A Martin
    Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, Fulham Road, London SW36JB, UK
    Steroids 76:772-6. 2011
    ..Furthermore analysis of temporal changes in gene expression during the acquisition of resistance highlight growth factor receptor pathways as key mediators of this adaptive process...
  53. pmc Aromatase inhibition: 4-hydroxyandrostenedione (4-OHA, CGP 32349) in advanced prostatic cancer
    J H Davies
    Department of Urology, St Georges Hospital, Tooting, London, UK
    Br J Cancer 66:139-42. 1992
    ..Further investigation of the effects of aromatase inhibitors on prostatic biology, and bone metabolism in patients with metastatic prostate cancer, would appear worthwhile...
  54. pmc Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial
    M Dowsett
    CRC and UCL Cancer Trials Centre, University College London, Stephenson House, 158 160 N Gower Street, London, NW1 2ND, UK
    Br J Cancer 85:317-24. 2001
    ....
  55. ncbi request reprint Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the impact trial
    S Banerjee
    Breast Unit, Royal Marsden Hospital, London and Sutton, London, UK
    Ann Oncol 16:1632-8. 2005
    ..The IMPACT trial evaluated neoadjuvant therapy with anastrozole or tamoxifen alone, or a combination. The comparative effects of these treatments on serum lipids and bone resorption were assessed...
  56. pmc The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer
    R C Stein
    Clinical Oncology Unit, St George s Hospital Medical School, London, UK
    Br J Cancer 62:679-83. 1990
    ..The combination of LHRH analogue and aromatase inhibitor may prove to be a superior treatment to LHRH analogue alone in these patients...
  57. doi request reprint Relationship between estrogen receptor, progesterone receptor, HER-2 and Ki67 expression and efficacy of aromatase inhibitors in advanced breast cancer
    H Anderson
    Academic Department of Biochemistry, Royal Marsden Hospital, London, UK
    Ann Oncol 22:1770-6. 2011
    ..Here, we aim to determine the effectiveness of AIs in that setting according to quantitative levels of estrogen receptor (ER), progesterone receptor (PgR) and Ki67 or human epithelial growth factor receptor-2 (HER-2) status...
  58. ncbi request reprint Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer
    L R Kelland
    CRC Centre for Cancer Therapeutics, The Institute of Cancer Research, Surrey SM2 5NG, United Kingdom
    Clin Cancer Res 7:3544-50. 2001
    ....
  59. pmc Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: effects on aromatase inhibition and oestrogen suppression
    F A MacNeill
    Section of Medicine, Royal Marsden Hospital, Surrey, UK
    Br J Cancer 69:1171-5. 1994
    ..2 +/- 9.1%, P < 0.025). This effect on Oe1S may be due to an influence of AG on oestrogen metabolism...
  60. pmc The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer
    M Dowsett
    Academic Department of Biochemistry, Royal Marsden Hospital, London, UK
    Br J Cancer 79:311-5. 1999
    ..In addition, the oestradiol suppressant effects of anastrozole appear unaffected by tamoxifen...
  61. ncbi request reprint Vorozole results in greater oestrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer
    M Dowsett
    Academic Department of Biochemistry, Royal Marsden Hospital, London, UK
    Breast Cancer Res Treat 56:25-34. 1999
    ..Existing clinical-pharmacological correlates suggest that these increases in pharmacological effectiveness may result in enhanced clinical effectiveness...
  62. ncbi request reprint Effects of the aromatase inhibitor anastrozole on serum oestrogens in Japanese and Caucasian women
    M Dowsett
    Department of Academic Biochemistry, Royal Marsden Hospital, London, UK
    Cancer Chemother Pharmacol 46:35-9. 2000
    ..Hence, the effects of the nonsteroidal aromatase inhibitor anastrozole on serum oestrogen concentrations were compared in 24 healthy postmenopausal Japanese women and 24 healthy postmenopausal Caucasian women...
  63. pmc A dose-comparative endocrine-clinical study of leuprorelin in premenopausal breast cancer patients
    M Dowsett
    Department of Biochemical Endocrinology, Royal Marsden Hospital, London, UK
    Br J Cancer 62:834-7. 1990
    ..We conclude that the slow release formulation of leuprorelin is effective in breast cancer treatment and that there is no major detriment to the use of the 3.75 rather than 7.5 mg dose...
  64. ncbi request reprint The pharmacology of letrozole
    B P Haynes
    Department of Academic Biochemistry, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
    J Steroid Biochem Mol Biol 87:35-45. 2003
    ..A consistent effect of letrozole on serum lipids has not been demonstrated...
  65. ncbi request reprint Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres
    M Dowsett
    Academic Department of Biochemistry, Royal Marsden NHS Trust, London, UK
    J Pathol 199:418-23. 2003
    ..These data support an algorithm in which FISH testing is restricted to IHC 2+ tumours in reference centres. The results may not extrapolate to laboratories with less experience or using different methodologies...
  66. ncbi request reprint A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer
    Ian E Smith
    Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom
    J Clin Oncol 25:3816-22. 2007
    ..We have therefore investigated whether neoadjuvant gefitinib, an EGFR inhibitor, might overcome biologic and clinical resistance to neoadjuvant anastrozole in a phase II placebo-controlled trial...
  67. ncbi request reprint Human epidermal growth factor receptor-2 and hormonal therapies: clinical implications
    Alistair Ring
    Department of Academic Biochemistry, Wallace Wing, Royal Marsden Hospital, London, United Kingdom
    Clin Breast Cancer 4:S34-41. 2003
    ..In contrast, early data from the neoadjuvant setting suggest that responses to aromatase inhibitors may be maintained in patients with HER2 overexpression...
  68. ncbi request reprint The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling
    L A Martin
    Academic Department of Biochemistry, Institute of Cancer Research, London, UK
    Endocr Relat Cancer 12:1017-36. 2005
    ..These results support the use of ICI in women with ER-positive breast cancer who have relapsed on an aromatase inhibitor...
  69. doi request reprint Enhanced expression of the PDGFR/Abl signaling pathway in aromatase inhibitor-resistant breast cancer
    M T Weigel
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Ann Oncol 24:126-33. 2013
    ..We aimed to determine its clinical relevance in aromatase inhibitor (AI)-resistant breast cancer...
  70. pmc Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer
    C D Archer
    Breast Unit, Royal Marsden NHS Trust, Fulham Road, London SW3 6JJ, UK
    Br J Cancer 89:1035-41. 2003
    ..Pretreatment proliferation and GI are however predictive of response to chemotherapy in breast cancer...
  71. pmc The novel anti-oestrogen idoxifene inhibits the growth of human MCF-7 breast cancer xenografts and reduces the frequency of acquired anti-oestrogen resistance
    S R Johnston
    Department of Academic Biochemistry, Royal Marsden Hospital, London, UK
    Br J Cancer 75:804-9. 1997
    ..The drug's reduced agonist activity may, in part, explain these observations and indicate a preferable biochemical profile for breast cancer treatment...
  72. pmc Comparison of in situ methods to assess DNA cleavage in apoptotic cells in patients with breast cancer
    P N Mainwaring
    Academic Department of Biochemistry, Royal Marsden Hospital, London, UK
    J Clin Pathol 51:34-7. 1998
    ..The use of biotinylated nucleotides to identify DNA strand breaks is a commonly reported method of estimating cells numbers undergoing apoptosis; however, investigators report inconsistent results for a variety of reasons...
  73. doi request reprint Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial
    Ivana Sestak
    Cancer Research UK UK, Queen Mary University of London, London, United Kingdom
    J Clin Oncol 28:3411-5. 2010
    ..As aromatase inhibitors work by inhibiting the conversion of androgens to estrogens in adipose tissue, we hypothesized that anastrozole may be more effective in women with a high body mass index (BMI)...
  74. ncbi request reprint Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention
    Catherine Harper-Wynne
    Academic Department of Biochemistry, Royal Marsden Hospital, London SW3 6JJ, United Kingdom
    Cancer Epidemiol Biomarkers Prev 11:614-21. 2002
    ..We conclude that any prophylactic effect of letrozole is not likely to be dependent on antiproliferative effects on normal breast. Studies in healthy patients will need to recognize the potential for enhanced bone resorption...
  75. ncbi request reprint Comparison of the selective estrogen receptor modulator arzoxifene (LY353381) with tamoxifen on tumor growth and biomarker expression in an MCF-7 human breast cancer xenograft model
    Simone Detre
    Academic Department of Biochemistry, The Royal Marsden NHS Trust, Fulham Road, London SW3 6JJ, U K
    Cancer Res 63:6516-22. 2003
    ..These results show that ARZ is an effective antagonist of E2-stimulated breast cancer growth with similar growth-inhibitory and pharmacodynamic effects to TAM in this model...
  76. ncbi request reprint Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance
    S R Johnston
    Department of Medicine, Royal Marsden Hospital and Institute of Cancer Research, London, England
    Clin Cancer Res 5:251-6. 1999
    ..These observations support the need for further evaluation of these markers in breast tumors as predictors of TAM resistance...
  77. ncbi request reprint Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer
    L Assersohn
    Breast Unit, Royal Marsden Hospital, Sutton, Surrey, UK
    Breast Cancer Res Treat 82:113-23. 2003
    ..Objectives were to characterise the relationship of the proliferation marker Ki67 with response to systemic treatment in early breast cancer and to assess its clinical utility, using fine needle aspirates...
  78. ncbi request reprint A cancer research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen
    S R D Johnston
    Cancer Research UK, Lincoln s Inn Fields, London, WC2A 3PX, UK
    Cancer Chemother Pharmacol 53:341-8. 2004
    ....
  79. pmc Measurement of S-phase fraction and ploidy in sequential fine-needle aspirates from primary human breast tumours treated with tamoxifen
    I N Fernando
    Department of Radiotherapy and Oncology, Royal Marsden Hospital, Surrey, UK
    Br J Cancer 70:1211-6. 1994
    ..We conclude that changes in ploidy and SPF detected by flow cytometry may predict initial response and the likelihood of relapse of breast tumours to tamoxifen before clinical changes become evident. These data justify a larger study...
  80. ncbi request reprint Theoretical considerations for the ideal aromatase inhibitor
    M Dowsett
    Royal Marsden Hospital, London, UK
    Breast Cancer Res Treat 49:S39-44; discussion S73-7. 1998
    ..The possibility is considered that the apparent small differences between the triazoles may be associated with differences in clinical effectiveness. These new compounds merit consideration for studies of breast cancer prevention...
  81. pmc Immunohistochemical assay for epidermal growth factor receptor on paraffin-embedded sections: validation against ligand-binding assay and clinical relevance in breast cancer
    J C Newby
    Department of Academic Biochemistry, Royal Marsden Hospital, London, UK
    Br J Cancer 71:1237-42. 1995
    ..02) and overall survival (P = 0.03) when measured by this immunohistochemical assay, but was not significant when measured by ligand-binding assay...
  82. pmc Therapeutic effects of the aromatase inhibitor fadrozole hydrochloride in advanced breast cancer
    H R Bonnefoi
    Royal Marsden Hospital and Institute of Cancer Research, London, UK
    Br J Cancer 73:539-42. 1996
    ..No serious adverse events were reported. In conclusion, fadrozole is a clinically active aromatase inhibitor with a low incidence of side-effects and phase III clinical trials in post-menopausal women are currently under way...
  83. doi request reprint Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC)
    M Arnedos
    Department of Medicine, Breast Unit, The Royal Marsden Hospital and Institute of Cancer Research, London, UK
    Ann Oncol 20:1948-52. 2009
    ....
  84. ncbi request reprint Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance
    I Plaza-Menacho
    Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Oncogene 29:4648-57. 2010
    ..Together these findings identify RET as a potentially important therapeutic target in ERalpha-positive breast cancers and in particular in tamoxifen-resistant tumors...
  85. ncbi request reprint Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (cytoxan) (AC) response and resistance
    Susan Cleator
    Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom
    Breast Cancer Res Treat 95:229-33. 2006
    ..We hypothesized that gene expression profiles predictive of AC response may be different from our previously published patterns with docetaxel...
  86. ncbi request reprint Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines
    Ian E Smith
    Royal Marsden Hospital Institute of Cancer Research, London, United Kingdom
    J Clin Oncol 24:2444-7. 2006
    ..Their use is sometimes extended to younger women after chemotherapy-induced amenorrhoea; we have audited this in one institution's breast unit, and we propose guidelines for use in such circumstances...
  87. doi request reprint Impact of estrogen deprivation on gene expression profiles of normal postmenopausal breast tissue in vivo
    Anne Kendall
    Department of Medical Oncology, Guys and St Thomas NHS Foundation Trust, London, UK
    Cancer Epidemiol Biomarkers Prev 17:855-63. 2008
    ..The modest degree of gene change suggests that intermediate markers of chemoprevention may be difficult to identify...
  88. ncbi request reprint Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer
    Edurne Arriola
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, Fulham Road, London SW3 6JB, UK
    Breast Cancer Res Treat 106:181-9. 2007
    ....
  89. ncbi request reprint Breast cancer molecular profiling with single sample predictors: a retrospective analysis
    Britta Weigelt
    Cancer Research UK, London Research Institute, London, UK
    Lancet Oncol 11:339-49. 2010
    ..Three microarray-based single sample predictors (SSPs) have been used to define molecular classification of individual samples. We aimed to establish agreement between these SSPs for identification of breast cancer molecular subtypes...
  90. ncbi request reprint The effects of neoadjuvant anastrozole and tamoxifen on circulating vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in breast cancer
    Susana Banerjee
    Breakthrough Breast Cancer Centre, Institute of Cancer Research, London, United Kingdom
    Clin Cancer Res 14:2656-63. 2008
    ..We investigated the effects of anastrozole and tamoxifen over time on serum VEGF and sVEGFR-1...
  91. ncbi request reprint Life following aromatase inhibitors--where now for endocrine sequencing?
    Stephen R Johnston
    Breast Unit, Department of Medicine, Royal Marsden Hospital NHS Trust, London, UK
    Breast Cancer Res Treat 93:S19-25. 2005
    ..The steroidal AI, exemestane is also an option in non-steroidal AI-resistant disease. Clinical trials are underway to compare fulvestrant with exemestane as an appropriate therapy following the onset of AI resistance...
  92. ncbi request reprint Aromatase inhibitors for breast cancer: lessons from the laboratory
    Stephen R D Johnston
    Breast Unit, Royal Marsden Hospital, London SW3 6JJ, UK
    Nat Rev Cancer 3:821-31. 2003
  93. ncbi request reprint Assessment of HER2 status in breast cancer: why, when and how?
    M Dowsett
    Academic Department of Biochemistry, Royal Marsden Hospital, London, UK
    Eur J Cancer 36:170-6. 2000
    ....
  94. ncbi request reprint The biology of neoadjuvant chemotherapy for breast cancer
    S Cleator
    Academic Department of Biochemistry, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
    Endocr Relat Cancer 9:183-95. 2002
    ..Continuing work using cDNA microarrays may yield new, more reliable indices of likely response and an improved insight into biological processes related to chemotherapeutic response...
  95. ncbi request reprint High incidence of HER-2 positivity in inflammatory breast cancer
    M Parton
    Breast Unit, Royal Marsden Hospital Trust and Institute of Cancer Research, Fulham Rd, London SW3 6JJ, UK
    Breast 13:97-103. 2004
    ..Early HER-2 directed therapy (such as the monoclonal antibody trastuzumab) as a part of multimodal treatment may improve outcome in this poor prognosis cancer...
  96. ncbi request reprint Comparative clinical pharmacology and pharmacokinetic interactions of aromatase inhibitors
    I M Boeddinghaus
    The Academic Department of Biochemistry, Royal Marsden Hospital, Fulham Road, SW3 6JJ, London, UK
    J Steroid Biochem Mol Biol 79:85-91. 2001
    ..Neither anastrozole nor letrozole have any effect on plasma concentrations of tamoxifen when given in combination with it...